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ABSTRACT
Clinic database extraction identiﬁed 806 new
entrants to human immunodeﬁciency virus (HIV)
care in Cleveland, OH, USA. At entry, women had
higher CD4 counts and lowerHIVRNA levels than
men (mean, 388 vs. 310 cells ⁄lL, and 8.94 · 104 vs.
1.27 · 105 copies ⁄mL, respectively), but the pro-
portion of entrants with category C illnesses,
category B conditions, sexually transmitted dis-
eases and CD4 counts < 200 lL did not differ
between genders. Hepatitis B seroprevalence was
higher in men (8.7% vs. 0.6%), but there was no
difference in hepatitis C prevalence. Whether
women in Cleveland seek HIV care earlier, or
whether early markers of HIV disease differ
between the genders, remains to be determined.
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According to the US Department of Health and
Human Services guidelines, CD4+ cell counts and
plasma human immunodeﬁciency virus (HIV)-1
RNA levels (viral load, VL) should be used to
guide initiation of anti-retroviral treatment [1].
The deﬁnition of AIDS is also based partly on
CD4+ counts, with CD4+ counts < 200 ⁄lL and ⁄ or
category C symptomatic conditions used to deﬁne
patients with AIDS [2]. Since cut-off points do not
take gender into account, the above guidelines
and deﬁnition are based on the assumption that
CD4+ cell counts and VL are comparable for both
genders. The aim of the present study was to
examine possible differences in CD4+ cell counts
and VL between HIV-infected men and women
new to HIV care in the era of highly active anti-
retroviral therapy (HAART).
Database extraction identiﬁed 1066 patients
who sought treatment for the ﬁrst time at the
CaseWestern Reserve University ⁄University Hos-
pitals of Cleveland Special Immunology Unit
(Cleveland, OH, USA) during the period 1995–
2002. Of these, 806 patients with no history of
AIDS-deﬁning illnesses in the 3 months before
presentation and no previous anti-retroviral expo-
sure were included in the present study. Informa-
tion was obtained concerning demographics,
category C AIDS-deﬁning illnesses and category
B symptomatic conditions (CDC Revised Classiﬁ-
cation System [2]) occurring before the initial visit
and up to 6 months afterwards, previous or
current sexually transmitted diseases (i.e., gonor-
rhoea, syphilis, chlamydia, herpes genital ⁄ anal,
trichomoniasis, genital or anal warts, molluscum
contagiosum; history and ⁄ or serology), presence
of hepatitis B surface antigen and antibody
(HBsAg ⁄HBsAb; Immulite 2000 Chemilumines-
cence Immunoassay; Immulite, Los Angeles, CA,
USA), hepatitis C antibody (HCV Ab; Ortho HCV
3.0 ELISA; Ortho, Raritan, NJ, USA), CD4+ lym-
phocyte counts (ﬂow cytometry) and VL (Ampli-
cor HIV-1 Monitor Assay; Roche, Branchburg, NJ,
USA) at baseline. The VL detection limit was
50 copies ⁄mL. Data were analysed using the t-test
for independent groups and v2 (SPSS v. 11.5; SPSS
Inc., Chicago, IL, USA). Analysis of co-variance
(ANCOVA) was used to assess the association of CD4
and VL after controlling for various co-variates.
In accordance with individuals living with
HIV ⁄AIDS in northeast Ohio, most (632; 78%) of
the 806 patients included in the study were men,
39% were non-Hispanic whites, 55% were Afri-
can-Americans, and 4% were Hispanics. The
median age was 36.3 years (range, 16.3–
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75.1 years). Males were older than females
(mean ± SD: 37.3 ± 8.7 vs. 35.1 ± 9.0 years,
respectively; p 0.005). Homosexual ⁄ bisexual men
represented 56% of the study group, and 33%
had a history of drug use.
The known duration of infection (time from
ﬁrst positive HIV test to seeking care for the ﬁrst
time) was similar for men and women (412 ± 596
vs. 374 ± 529 days, respectively; p 0.541) The
cumulative proportions of patients presenting
with category C AIDS-deﬁning illnesses or cate-
gory B conditions were similar among men and
women (Table 1). There was no signiﬁcant differ-
ence in the frequency of sexually transmitted
diseases between males and females. The overall
seroprevalences of hepatitis B (HBsAg+) and
hepatitis C infections were 7% and 18%, respect-
ively, with an overall prevalence of HBsAb of
31%. The seroprevalence of hepatitis B was
higher in men, but there was no signiﬁcant
difference in hepatitis C antibody (Table 1).
CD4+ cell counts and plasma HIV RNA in
new entrants were 327 ± 253 cells ⁄ lL and
1.22 · 105 ± 2.08 · 105 copies ⁄mL. Women had
higher CD4+ counts and lower HIV RNA VL than
men at baseline, and these differences persisted
after controlling for age, race and other baseline
characteristics. Approximately one-third (36%) of
new entrants to care had CD4+ cell counts
< 200 ⁄ lL, and this proportion did not differ
signiﬁcantly between genders (Table 2). Further
analysis divided patients into sub-populations: (1)
according to the absence (group Ia) or presence
(group Ib) of category C symptomatic conditions;
and (2) according to whether CD4+ cell counts
were ‡ 200 ⁄ lL (group IIa) or < 200 ⁄ lL (group IIb)
at presentation. The gender difference in CD4+
counts was preserved for groups Ia and IIa, but
not for groups Ib and IIb. There was no difference
between the genders for HIV RNA VL in any of
the above groups (Table 2).
The beneﬁcial effects of HAART are well-estab-
lished [3,4], and the overall mortality and inci-
dence of severe opportunistic infections have
declined signiﬁcantly since 1995 [5], perhaps
motivating more individuals at risk to be screened
for HIV infection. In the present study, women
presenting for the ﬁrst time for HIV care had lower
plasma VL and higher CD4+ cell counts than did
new male entrants to care. However, women
could be presenting earlier for HIV testing and
care than men, and additional data concerning
seroconversion are needed to investigate this
possibility. On the other hand, although women
had higher CD4+ cell counts, this difference was
only apparent in individuals presenting at an early
stage of the disease (without category C conditions
and with CD4+ cell counts > 200 ⁄lL), which could
be interpreted as suggesting differences in cellular
support for HIV replication between men and
women at this early stage. This possibility is also
suggested by a recent study [6] indicating gender
differences in HIV vertical acquisition, although
the mechanisms for this possible gender-depend-
ent susceptibility remain unknown.
There are conﬂicting reports concerning the
existence of gender-dependent differences in VL
and CD4+ cell counts. Some studies have found
median VLs in women to be only 38–65% of those
in men [7–10], while others [11,12] have found no
gender differences. The EuroSIDA study [10]
Table 1. CDC category C AIDS-deﬁning illnesses, cate-
gory B symptomatic conditions, sexually transmitted
diseases and markers for hepatitis B and C viruses among
male and female new entrants to human immunodeﬁ-
ciency virus care
Males (n = 632) Females (n = 174) p
Patients with category C
illnesses, n (%)
100 (15.8) 21 (12.0) 0.23, NS
Patients with category B
conditions, n (%)
176 (27.8) 52 (29.8) 0.63, NS
Patients with current or
past STDs, n (%)
112 (17.7) 26 (14.9) 0.42, NS
Patients with positive
HBsAg, n (%)
45 ⁄ 515a (8.7) 1 ⁄ 153a (0.6) <0.001
Patients with positive
HCV Ab, n (%)
97 ⁄ 515a (18.8) 24 ⁄ 153a (15.6) 0.405, NS
STD, sexually transmitted disease; NS, non-signiﬁcant; HBsAg, hepatitis B surface
antigen; HCV Ab, hepatitis C virus antibody.
aPatients screened for HBsAg ⁄HBsAb and HCV Ab.
Table 2. CD4+ cell counts and plasma HIV RNA levels in
males and females at presentation
Men (n = 632) Women (n = 174) p
CD4+ cell count, cells ⁄ lL ± SD
All patients 310 ± 242 388 ± 282 0.003
Group Ia: Category C– 351 ± 239 430 ± 280 0.014
Group Ib: Category C+ 90 ± 124 109 ± 122 0.62, NS
Group IIa: CD4+ ‡ 200 ⁄ lL 455 ± 194 512 ± 238 0.031
Group IIb: CD4+ < 200 ⁄ lL 72 ± 63 81 ± 70 0.49, NS
HIV RNA, · 104 copies ⁄mL ± SD
All patients 12.65 ± 20.05 8.94 · 104 ± 16.82 0.048
Group Ia: Category C– 10.38 ± 18.53 7.74 ± 16.41 0.21, NS
Group Ib: Category C+ 26.34 ± 23.26 19.34 ± 19.26 0.31, NS
Group IIa: CD4 ‡ 200 ⁄ lL 6.08 ± 12.21 3.74 ± 8.83 0.12, NS
Group IIb: CD4 < 200 ⁄ lL 23.62 ± 25.22 21.58 ± 23.94 0.67, NS
Entrants with CD4+
< 200 ⁄ lL, n(%)
197 ⁄ 507a (37.8) 43 ⁄ 141a (30.4) 0.114, NS
HIV, human immunodeﬁciency virus; NS, non-signiﬁcant.
aPatients with available CD4+ cell counts at baseline.
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reported higher CD4+ cell counts in women, while
Farzadegan et al. [7] found very similar counts for
both genders. Since the present ﬁndings do not
apply to individuals presenting with category C
conditions or CD4+ cell counts < 200 ⁄lL, it would
seem that there is no need to establish gender-
dependent thresholds in this population to guide
initiation of treatment. However, it might be
worth reconsidering the threshold for asympto-
matic women presenting with CD4+ counts
> 200 ⁄lL so that they receive highly active anti-
retroviral therapy at an earlier stage in the disease.
There are several limitations to these ﬁndings.
First, self-reported data are subject to recall bias or
to other reporting errors. Second, as in all retro-
spective studies, some data may be missing or
incorrectly entered. Third, this study population,
considered to represent patients seeking care for
the ﬁrst time, may also include a small number of
people who had sought care elsewhere and, in the
absence of preceding AIDS-deﬁning illnesses,
were not treated with anti-retroviral therapies.
Nevertheless, this retrospective analysis found
that new female entrants to HIV care had higher
CD4+ cell counts and lower VLs, and were less
likely to be seropositive for hepatitis B infection.
Whether women in Cleveland seek HIV testing
earlier, or whether early markers of HIV disease
differ between the genders, remains to be deter-
mined.
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ABSTRACT
This study evaluated the role of linezolid in the
treatment of patients suffering from pneumococ-
cal meningitis. Treatment included ceftriaxone
(4000 mg every 24 h), linezolid (600 mg every
12 h) and dexamethasone (8 mg every 6 h).
Linezolid was withdrawn if a penicillin-suscept-
ible isolate of Streptococcus pneumoniae was iden-
tiﬁed. Of 16 patients studied, seven were infected
with penicillin-non-susceptible isolates of S. pneu-
moniae, two died, and three reported sequelae. No
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